Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 13, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how the timing of pembrolizumab infusions affects treatment outcomes for women with non-metastatic triple-negative breast cancer (TNBC). Pembrolizumab is a type of immunotherapy that helps the immune system fight cancer. The study aims to see if receiving this treatment in the morning versus the afternoon impacts the tumor's response to therapy and the length of time patients remain free from cancer after treatment.
To participate in this trial, women must be at least 18 years old, have been diagnosed with early-stage TNBC, and have not received any prior treatment for their cancer. Participants will receive a combination of chemotherapy and pembrolizumab, and their treatment schedules will be closely monitored. The trial is currently not recruiting participants, but it is important for those eligible to know that they will be contributing to research that could improve future cancer treatments.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female sex
- • Age ≥ 18 years-old
- • Previously untreated histologically proven triple-negative breast cancer (RE \< 10%, RP \< 10%, Her-2 negative)
- • No metastatic
- • Having at least one injection of pembrolizumab associated with chemotherapy
- • Pembrolizumab injection schedule correctly reported by the nurse in charge of the patient
- Exclusion Criteria:
- • • Metastatic disease
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported